Immunophotonics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Immunophotonics's estimated annual revenue is currently $1.8M per year.(i)
  • Immunophotonics's estimated revenue per employee is $100,500

Employee Data

  • Immunophotonics has 18 Employees.(i)
  • Immunophotonics grew their employee count by 64% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2233.5M694516%N/AN/A
#2
$11.5M572%N/AN/A
#3
$13.7M68-8%N/AN/A
#4
$11.5M5710%N/AN/A
#5
$42M2094%N/AN/A
#6
$1.8M1864%N/AN/A
#7
$6.8M34-13%N/AN/A
#8
$9.2M462%N/AN/A
#9
$1099.9M34200%$97MN/A
#10
$18.5M920%N/AN/A
Add Company

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$1.8M

Revenue (est)

64%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M18-14%N/A
#2
$2.3M18-31%N/A
#3
$2.9M1829%N/A
#4
$1.6M18-18%N/A
#5
$2.9M18-49%N/A